Active bacterial modification of the host environment through RNA polymerase II inhibition

J Clin Invest. 2021 Feb 15;131(4):e140333. doi: 10.1172/JCI140333.

Abstract

Unlike pathogens, which attack the host, commensal bacteria create a state of friendly coexistence. Here, we identified a mechanism of bacterial adaptation to the host niche, where they reside. Asymptomatic carrier strains were shown to inhibit RNA polymerase II (Pol II) in host cells by targeting Ser2 phosphorylation, a step required for productive mRNA elongation. Assisted by a rare, spontaneous loss-of-function mutant from a human carrier, the bacterial NlpD protein was identified as a Pol II inhibitor. After internalization by host cells, NlpD was shown to target constituents of the Pol II phosphorylation complex (RPB1 and PAF1C), attenuating host gene expression. Therapeutic efficacy of a recombinant NlpD protein was demonstrated in a urinary tract infection model, by reduced tissue pathology, accelerated bacterial clearance, and attenuated Pol II-dependent gene expression. The findings suggest an intriguing, evolutionarily conserved mechanism for bacterial modulation of host gene expression, with a remarkable therapeutic potential.

Keywords: Immunotherapy; Inflammation; Microbiology; Transcription.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Escherichia coli Infections* / genetics
  • Escherichia coli Infections* / immunology
  • Escherichia coli Proteins* / genetics
  • Escherichia coli Proteins* / immunology
  • Escherichia coli* / genetics
  • Escherichia coli* / immunology
  • Female
  • Gene Expression Regulation, Bacterial / immunology*
  • Humans
  • Lipoproteins* / genetics
  • Lipoproteins* / immunology
  • Mice
  • RNA Polymerase II* / genetics
  • RNA Polymerase II* / immunology
  • Urinary Tract Infections* / genetics
  • Urinary Tract Infections* / immunology

Substances

  • Escherichia coli Proteins
  • Lipoproteins
  • NlpD protein, E coli
  • RNA Polymerase II

Grants and funding

’The Nice Bug consortium’